Danaher to Acquire Aldevron

Danaher Corporation (NYSE: DHR) (the “Company”) announced today that Danaher has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. Founded in 1998 by Michael Chambers and John Ballantyne, Aldevron is headquartered in Fargo, North Dakota and employs approximately 600 people. Aldevron manufactures high-quality plasmid DNA, mRNA, and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications.

Explora BioLabs Acquires Cambridge Vivarium Service Provider Novalex

Explora BioLabs, a national provider of preclinical vivarium space, vivarium management services, and contract research services, today announced it has completed its acquisition of Novalex Biotech Resources, LLC, a vivarium service provider based here. The acquisition expands Explora BioLabs’ OnSite vivarium management services to the Boston-area biotechnology market.

Elligo Health Research Acquires Root Health as Growth Accelerates

Elligo Health Research announced Tuesday the acquisition of Root Health, an AI virtual assistant for clinical research. The acquisition of Root Health adds to Elligo’s commitment of building a technology-forward, integrated healthcare-enabling research organization with a full range of capabilities to improve the efficiency of clinical research and is designed to support easy access for faster enrollment and accelerated trials overall.

Alira Health Expands Its Global Clinical and Data Capabilities through the Acquisition of CROS NT

Alira Health, a leading international healthcare and life sciences advisory services firm, announced that it has acquired CROS NT, a data-driven Contract Research Organization (CRO) headquartered in Italy with offices across Europe and the United States. CROS NT provides high quality, cost-effective biometrics and innovative solutions to help clients develop and deliver therapeutics and diagnostics that improve patient lives around the world.

Novo Integrated Sciences Enters into Share Exchange Agreement to Acquire Acenzia Inc.

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company”) is pleased to announce the signing of a Share Exchange Agreement, dated May 28, 2021 (the “SEA”), pursuant to which Novo Healthnet Limited, a wholly owned subsidiary of the Company (“NHL”) will acquire Acenzia Inc., which is in the business of providing nutraceutical health solutions through advanced bio-science research and development, proprietary manufacturing, and personalized diagnostics.

Aceto Propels Growth Strategy with Cascade Chemistry Acquisition

Aceto, a leading global provider of specialty materials for life sciences and advanced technology end markets, announced today the acquisition of Eugene, Oregon-based Cascade Chemistry, manufacturer of active pharmaceutical ingredients (APIs), regulatory starting materials and advanced intermediates. With this acquisition, Aceto now provides customers enhanced support throughout the drug development process and greater access to expanded North American manufacturing, particularly for APIs and advanced intermediates.

Webster Gears up for Sale of CenExel

Pre-covid, CROs and pharma companies would look to dozens of clinical research sites to execute their studies, but managing a large collections of sites has proven less efficient through the pandemic, PE Hub’s Sarah Pringle is told. That dynamic is likely to bode well for one such asset preparing for a sale — CenExel Clinical Research, a portfolio company of Webster Equity Partners. CenExel, a clinical site organization, has a concentrated model with facilities of scale offering centralized capabilities. Fireside chats are currently taking place, with a sponsor-focused sale process poised to launch soon.

CVS Health Launching New Business Arm to Drive Greater Clinical Trial Participation

CVS Health has launched a new business arm that aims to drive greater, and more diverse, participation in clinical trials. CVS Health’s new Clinical Trials Services business focuses on three core areas: patient recruitment, delivering clinical trials in multiple ways and generating real-world evidence on therapies and devices. Owen Garrick, M.D., vice president of clinical trial delivery at CVS Health Clinical Trial Services, told Fierce Healthcare that the team is building on decades of work at CVS to build community ties and relationships with pharmaceutical companies.

Riverside Signs Definitive Agreement to Sell Greenphire to Thoma Bravo

The Riverside Company, a global private investor focused on the smaller end of the middle market, has signed a definitive agreement to sell Greenphire, the global leader in financial lifecycle management software for clinical trials, to Thoma Bravo, a software focused private equity firm. Founded in 2008, Greenphire enables pharmaceutical industry leaders worldwide to run more efficient and successful clinical trials. The company’s end-to-end solutions optimize clinical trial performance by streamlining financial management, payment and logistical workflows from sponsors and contract research organizations (CROs) to sites and patients in more than 70 countries.

CATO SMS Acquires Nuventra to Expand Drug Development Offering into Clinical Pharmacology

CATO SMS, a global provider of regulatory and clinical research services, announced Wednesday that it has acquired Nuventra, Inc. to extend its offering into the critical area of clinical pharmacology. Headquartered in Durham, N.C., Nuventra is one of the industry’s leading clinical pharmacology science and services providers. The acquisition expands CATO SMS’ portfolio of specialized solutions that support biopharmaceutical companies with drug development, adding a key set of capabilities focused on significantly reducing development risk, costs and timelines.